Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Dyne Therapeutics Inc
CEO
Mr. John G. Cox M.B.A.
Employees
173
Industry
Biotechnology
Sector
Healthcare
Market cap
$3B
Company details
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.55
Margin profit
0.00%
52 week low
$15.62
52 week high
$47.040001
50-day simple moving average
$0.00
200-day simple moving average
$34.31
Percent held by insiders
0.48%
Percent held by institutions
112.41%
Dividend yield
0.00%
